GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
2.5k
c/tirzepatide·posted 11 months ago by u/mikkel_kimani

the GIP question that gets asked weekly, answered properly

Titration Cold Box ×2 The Quiet One ×3

Posting this as a discussion rather than a claim: the GIP question that gets asked weekly, answered properly.

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.

2,891 up / 389 down88% upvoted59 commentsid psz24f21 Aug 2025

59 comments

25 in this archive, depth 4

best — the order this archive was captured in

u/crosspost_bot_no395 points·11 months ago

On comparing yourself with the trial number.

SURMOUNT-1 reported roughly 21% mean body weight change at 72 weeks on the highest arm. Three things get dropped every time that figure is quoted here. It is a mean, and the distribution around it is very wide. It is 72 weeks, which is a year and a half. And it is a trial population with trial support, which is not the same as a person with a spreadsheet.

Use it as a rough shape, not a benchmark. A 12% year is inside the ordinary range and people quit over it every week on this board.

replysharereportpermalink
u/aksel_kjaer219 points·11 months ago

Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.

replysharereportpermalink
u/laila_yilmaz138 points·11 months ago

Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.

replysharereportpermalink
u/halima_boateng107 points·11 months ago

Not sure that follows. You went up a step and changed your training in the same fortnight.

replysharereportpermalink
u/amara_halonen162 points·11 months ago

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

replysharereportpermalink
u/ghrp_history177 points·11 months ago

pens and vials are the same molecule, the price is the difference

replysharereportpermalink
u/signe_villalobos66 points·11 months ago

Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.

replysharereportpermalink
u/tove_vasquez53 points·11 months ago

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

replysharereportpermalink
u/sten_palacios79 points·11 months ago

Week 7 was the first time the scale moved after a five-week stall. I changed nothing in that window.

replysharereportpermalink
u/ghrp_history119 points·11 months ago

the fatigue profile is genuinely gentler than people expect coming from sema

replysharereportpermalink
u/b12_baseline52 points·11 months ago

I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your food noise pattern is a guess.

replysharereportpermalink
u/zeynep_ndiaye39 points·11 months ago

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink
u/bastian_ekstrom32 points·11 months ago·edited

The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 34 is not a fair reading.

replysharereportpermalink
[removed]24 points·11 months ago

[removed by moderator]

replysharereportpermalink
u/kaia_cabrera123 points·11 months ago

16kg over 42 weeks, never went past 10mg, and fatigue stayed mild the whole way. Posting because the loud threads are all 15mg.

replysharereportpermalink
u/quiet_moderatorMOD88 points·11 months ago·edited

Left up, flair changed to Discussion. It is an opinion post and that is fine as long as it is labelled.

replysharereportpermalink
u/piotr_nascimento-34 points·11 months ago

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

replysharereportpermalink
u/ghrp_history1 point·11 months ago

Correction to my own post above — I said 7.5mg and I have been on 15mg since the spring. Same argument, wrong number.

replysharereportpermalink
u/hassan_nilsen59 points·11 months ago

hold the dose that works, the ladder is not a leaderboard

replysharereportpermalink
u/ewan_marchand70 points·11 months ago

sulphur burps are the signature complaint and they are not dangerous

replysharereportpermalink
u/kian_ekstrom50 points·11 months ago

a lot of people plateau nicely at 10mg and never need 15

replysharereportpermalink
u/fatima_wojcik13 points·11 months ago

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

replysharereportpermalink
u/georgi_chowdhury3 points·11 months ago

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

replysharereportpermalink
u/dario_vermeulen1 point·11 months ago

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

replysharereportpermalink
u/tarek_kirchner8 points·11 months ago·edited

Research-use-only material is not approved for human use.

Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.